- AstraZeneca's experimental daily weight loss pill, elecoglipron, has shown promising results in phase II trials, leading to significant body weight reduction and improved blood sugar levels for those with type 2 diabetes.
- In the Vista trial, overweight or obese participants without type 2 diabetes lost 10.5 per cent of their body weight at 26 weeks with the highest dose, also experiencing lower blood pressure and inflammation.
- The Solstice trial found that, compared to a placebo, elecoglipron was more effective in lowering blood sugar and promoting weight loss in individuals with type 2 diabetes and a body mass index higher than 23.
- A key distinction of elecoglipron is its administration as a daily tablet, and it does not require fasting as associated with other weight loss pills.
- Common side effects reported across both trials – published in the Lancet – included nausea, diarrhoea, constipation and vomiting.
IN FULL
